Researchers at Harvard Medical School have discovered a possible link between multiple sclerosis (MS) and the Epstein-Barr virus.  Epstein Barr is carried by approximately 95% of adults, and although it can be connected to mononucleosis and some rare cancers, most people are unaffected by the virus.

MS is considered to be an autoimmune disease. However, a new Harvard Medical School study points to evidence that MS may actually be a complication of the Epstein Barr virus. If this is the case, then antivirals that target Epstein Barr could be used to treat MS in the future. Even more promising is the fact that Moderna – the drug company that created the mRNA vaccine against COVID-19 – has begun phase 1 trials of an Epstein Barr vaccine. While it’s still too early to tell, if MS is truly a complication of the Epstein Barr virus, then antivirals and vaccines may help put an end to MS and the devastating effects it often has on those with the disease.

Accessibility Services, Inc. is honored to work with individuals with MS, helping those with the most progressive forms of the disease reclaim their independence.  It is our sincerest hope that this promising new research will help make MS a disease of the past.

Read more about this breakthrough Epstein-Barr and MS research.